PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis
NASDAQ:PRVA - Nasdaq - US74276R1023 - Common Stock - Currency: USD
Overall PRVA gets a fundamental rating of 4 out of 10. We evaluated PRVA against 103 industry peers in the Health Care Providers & Services industry. PRVA has a great financial health rating, but its profitability evaluates not so good. PRVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PRVA was profitable.
In the past year PRVA had a positive cash flow from operations.
In multiple years PRVA reported negative net income over the last 5 years.
PRVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
PRVA has a Return On Assets (1.32%) which is in line with its industry peers.
PRVA has a Return On Equity (2.37%) which is comparable to the rest of the industry.
PRVA has a Return On Invested Capital of 2.00%. This is comparable to the rest of the industry: PRVA outperforms 44.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.32% | ||
| ROE | 2.37% | ||
| ROIC | 2% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRVA's Profit Margin of 0.87% is in line compared to the rest of the industry. PRVA outperforms 54.37% of its industry peers.
PRVA's Profit Margin has declined in the last couple of years.
PRVA has a Operating Margin of 1.19%. This is comparable to the rest of the industry: PRVA outperforms 44.66% of its industry peers.
PRVA's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 10.09%, PRVA is doing worse than 76.70% of the companies in the same industry.
In the last couple of years the Gross Margin of PRVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.19% | ||
| PM (TTM) | 0.87% | ||
| GM | 10.09% |
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PRVA is destroying value.
PRVA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PRVA has been increased compared to 5 years ago.
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PRVA has an Altman-Z score of 4.86. This indicates that PRVA is financially healthy and has little risk of bankruptcy at the moment.
PRVA's Altman-Z score of 4.86 is amongst the best of the industry. PRVA outperforms 80.58% of its industry peers.
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.86 |
ROIC/WACC0.22
WACC8.93%
2.3 Liquidity
A Current Ratio of 1.88 indicates that PRVA should not have too much problems paying its short term obligations.
The Current ratio of PRVA (1.88) is better than 68.93% of its industry peers.
PRVA has a Quick Ratio of 1.88. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.88, PRVA is doing good in the industry, outperforming 72.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 |
3. Growth
3.1 Past
The earnings per share for PRVA have decreased strongly by -20.00% in the last year.
Measured over the past 5 years, PRVA shows a small growth in Earnings Per Share. The EPS has been growing by 7.43% on average per year.
Looking at the last year, PRVA shows a small growth in Revenue. The Revenue has grown by 6.79% in the last year.
The Revenue has been growing by 17.17% on average over the past years. This is quite good.
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%50%
Revenue 1Y (TTM)6.79%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%12.84%
3.2 Future
PRVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.51% yearly.
Based on estimates for the next years, PRVA will show a small growth in Revenue. The Revenue will grow by 0.21% on average per year.
EPS Next Y90.75%
EPS Next 2Y76.06%
EPS Next 3Y62.51%
EPS Next 5YN/A
Revenue Next Year11.86%
Revenue Next 2Y11.19%
Revenue Next 3Y11.67%
Revenue Next 5Y0.21%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 182.67, which means the current valuation is very expensive for PRVA.
Compared to the rest of the industry, the Price/Earnings ratio of PRVA is on the same level as its industry peers.
PRVA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.28.
A Price/Forward Earnings ratio of 64.29 indicates a quite expensive valuation of PRVA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PRVA is on the same level as its industry peers.
PRVA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.76.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 182.67 | ||
| Fwd PE | 64.29 |
4.2 Price Multiples
62.14% of the companies in the same industry are cheaper than PRVA, based on the Enterprise Value to EBITDA ratio.
PRVA's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. PRVA is cheaper than 60.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.58 | ||
| EV/EBITDA | 76.7 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PRVA does not grow enough to justify the current Price/Earnings ratio.
PRVA's earnings are expected to grow with 62.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.01
PEG (5Y)24.57
EPS Next 2Y76.06%
EPS Next 3Y62.51%
5. Dividend
5.1 Amount
No dividends for PRVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.92
-0.62 (-2.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.99%
Inst Owner Change1.52%
Ins Owners1.86%
Ins Owner Change0.88%
Market Cap2.67B
Analysts84.29
Price Target31.21 (42.38%)
Short Float %3.01%
Short Ratio4.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.31%
Min EPS beat(2)-40.79%
Max EPS beat(2)-37.83%
EPS beat(4)0
Avg EPS beat(4)-38.4%
Min EPS beat(4)-40.79%
Max EPS beat(4)-36.27%
EPS beat(8)1
Avg EPS beat(8)-32.84%
EPS beat(12)5
Avg EPS beat(12)107.25%
EPS beat(16)8
Avg EPS beat(16)62.22%
Revenue beat(2)2
Avg Revenue beat(2)4.34%
Min Revenue beat(2)0.75%
Max Revenue beat(2)7.92%
Revenue beat(4)4
Avg Revenue beat(4)2.8%
Min Revenue beat(4)0.75%
Max Revenue beat(4)7.92%
Revenue beat(8)8
Avg Revenue beat(8)2.56%
Revenue beat(12)8
Avg Revenue beat(12)-7.79%
Revenue beat(16)10
Avg Revenue beat(16)-10%
PT rev (1m)3.38%
PT rev (3m)6.96%
EPS NQ rev (1m)0.46%
EPS NQ rev (3m)-16.28%
EPS NY rev (1m)-0.69%
EPS NY rev (3m)-20.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.08%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 182.67 | ||
| Fwd PE | 64.29 | ||
| P/S | 1.48 | ||
| P/FCF | 22.58 | ||
| P/OCF | 22.58 | ||
| P/B | 4.05 | ||
| P/tB | 6.52 | ||
| EV/EBITDA | 76.7 |
EPS(TTM)0.12
EY0.55%
EPS(NY)0.34
Fwd EY1.56%
FCF(TTM)0.97
FCFY4.43%
OCF(TTM)0.97
OCFY4.43%
SpS14.77
BVpS5.41
TBVpS3.36
PEG (NY)2.01
PEG (5Y)24.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.32% | ||
| ROE | 2.37% | ||
| ROCE | 3% | ||
| ROIC | 2% | ||
| ROICexc | 5.87% | ||
| ROICexgc | N/A | ||
| OM | 1.19% | ||
| PM (TTM) | 0.87% | ||
| GM | 10.09% | ||
| FCFM | 6.57% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-10.22%
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
F-Score6
Asset Turnover1.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 111.34 | ||
| Cash Conversion | 412.04% | ||
| Profit Quality | 757.69% | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 | ||
| Altman-Z | 4.86 |
F-Score6
WACC8.93%
ROIC/WACC0.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%50%
EPS Next Y90.75%
EPS Next 2Y76.06%
EPS Next 3Y62.51%
EPS Next 5YN/A
Revenue 1Y (TTM)6.79%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%12.84%
Revenue Next Year11.86%
Revenue Next 2Y11.19%
Revenue Next 3Y11.67%
Revenue Next 5Y0.21%
EBIT growth 1Y45%
EBIT growth 3YN/A
EBIT growth 5Y1.07%
EBIT Next Year515.6%
EBIT Next 3Y106.09%
EBIT Next 5Y64.58%
FCF growth 1Y202.94%
FCF growth 3Y26.09%
FCF growth 5Y42.42%
OCF growth 1Y202.4%
OCF growth 3Y25.67%
OCF growth 5Y35.01%